These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 28011910)

  • 61. Cross-neutralizing Anti-hemagglutinin Antibodies Isolated from Patients Infected with Avian Influenza A (H5N1) Virus.
    Sun Y; Cao Y; Li Z; Bai T; Zhang H; Hu SX; Li FC; Zhao X; Chen YK; Lu J; Liu LQ; Wang DY; Shu YL; Zhou JF
    Biomed Environ Sci; 2020 Feb; 33(2):103-113. PubMed ID: 32131957
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A broadly protective human monoclonal antibody targeting the sialidase activity of influenza A and B virus neuraminidases.
    Yasuhara A; Yamayoshi S; Kiso M; Sakai-Tagawa Y; Okuda M; Kawaoka Y
    Nat Commun; 2022 Nov; 13(1):6602. PubMed ID: 36329075
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Antibody Responses with Fc-Mediated Functions after Vaccination of HIV-Infected Subjects with Trivalent Influenza Vaccine.
    Kristensen AB; Lay WN; Ana-Sosa-Batiz F; Vanderven HA; Madhavi V; Laurie KL; Carolan L; Wines BD; Hogarth M; Wheatley AK; Kent SJ
    J Virol; 2016 Jun; 90(12):5724-5734. PubMed ID: 27053553
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A contributing role for anti-neuraminidase antibodies on immunity to pandemic H1N1 2009 influenza A virus.
    Marcelin G; DuBois R; Rubrum A; Russell CJ; McElhaney JE; Webby RJ
    PLoS One; 2011; 6(10):e26335. PubMed ID: 22039464
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A VLP vaccine induces broad-spectrum cross-protective antibody immunity against H5N1 and H1N1 subtypes of influenza A virus.
    Wu CY; Yeh YC; Chan JT; Yang YC; Yang JR; Liu MT; Wu HS; Hsiao PW
    PLoS One; 2012; 7(8):e42363. PubMed ID: 22879951
    [TBL] [Abstract][Full Text] [Related]  

  • 66. An H5N1-based matrix protein 2 ectodomain tetrameric peptide vaccine provides cross-protection against lethal infection with H7N9 influenza virus.
    Leung HC; Chan CC; Poon VK; Zhao HJ; Cheung CY; Ng F; Huang JD; Zheng BJ
    Emerg Microbes Infect; 2015 Apr; 4(4):e22. PubMed ID: 26038770
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Protection against influenza H7N9 virus challenge with a recombinant NP-M1-HSP60 protein vaccine construct in BALB/c mice.
    Yang P; Wang W; Gu H; Li Z; Zhang K; Wang Z; Li R; Duan Y; Zhang S; Wang X
    Antiviral Res; 2014 Nov; 111():1-7. PubMed ID: 25173575
    [TBL] [Abstract][Full Text] [Related]  

  • 68. What Lies Beneath: Antibody Dependent Natural Killer Cell Activation by Antibodies to Internal Influenza Virus Proteins.
    Vanderven HA; Ana-Sosa-Batiz F; Jegaskanda S; Rockman S; Laurie K; Barr I; Chen W; Wines B; Hogarth PM; Lambe T; Gilbert SC; Parsons MS; Kent SJ
    EBioMedicine; 2016 Jun; 8():277-290. PubMed ID: 27428437
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Cross-protective immunity against multiple influenza virus subtypes by a novel modified vaccinia Ankara (MVA) vectored vaccine in mice.
    Brewoo JN; Powell TD; Jones JC; Gundlach NA; Young GR; Chu H; Das SC; Partidos CD; Stinchcomb DT; Osorio JE
    Vaccine; 2013 Apr; 31(14):1848-55. PubMed ID: 23376279
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Human antibody responses to avian influenza A(H7N9) virus, 2013.
    Guo L; Zhang X; Ren L; Yu X; Chen L; Zhou H; Gao X; Teng Z; Li J; Hu J; Wu C; Xiao X; Zhu Y; Wang Q; Pang X; Jin Q; Wu F; Wang J
    Emerg Infect Dis; 2014 Feb; 20(2):192-200. PubMed ID: 24447423
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Safety and immunogenicity of seasonal inactivated influenza vaccine (split virion) and cross-reactive antibody responses to the H7N9 avian influenza virus].
    Guo W; Xu J; Wu J; Zhao S; He H; Shi W; Yu D; Li J; Gao H; Chen J
    Zhonghua Liu Xing Bing Xue Za Zhi; 2014 Aug; 35(8):949-52. PubMed ID: 25376689
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Hemagglutinin and Neuraminidase Antibodies Are Induced in an Age- and Subtype-Dependent Manner after Influenza Virus Infection.
    Wong SS; Waite B; Ralston J; Wood T; Reynolds GE; Seeds R; Newbern EC; Thompson MG; Huang QS; Webby RJ;
    J Virol; 2020 Mar; 94(7):. PubMed ID: 31941786
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Incorporation of conserved nucleoprotein into influenza virus-like particles could provoke a broad protective immune response in BALB/c mice and chickens.
    Xue C; Tian G; Chen X; Liu Q; Ma J; Xu S; Li X; Chen H; Cao Y
    Virus Res; 2015 Jan; 195():35-42. PubMed ID: 25312452
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Human cytotoxic T lymphocytes directed to seasonal influenza A viruses cross-react with the newly emerging H7N9 virus.
    van de Sandt CE; Kreijtz JH; de Mutsert G; Geelhoed-Mieras MM; Hillaire ML; Vogelzang-van Trierum SE; Osterhaus AD; Fouchier RA; Rimmelzwaan GF
    J Virol; 2014 Feb; 88(3):1684-93. PubMed ID: 24257602
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Single-dose vaccination of a recombinant parainfluenza virus 5 expressing NP from H5N1 virus provides broad immunity against influenza A viruses.
    Li Z; Gabbard JD; Mooney A; Gao X; Chen Z; Place RJ; Tompkins SM; He B
    J Virol; 2013 May; 87(10):5985-93. PubMed ID: 23514880
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Universal Influenza Virus Neuraminidase Vaccine Elicits Protective Immune Responses against Human Seasonal and Pre-pandemic Strains.
    Skarlupka AL; Bebin-Blackwell AG; Sumner SF; Ross TM
    J Virol; 2021 Aug; 95(17):e0075921. PubMed ID: 34160258
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Identification of dominant antibody-dependent cell-mediated cytotoxicity epitopes on the hemagglutinin antigen of pandemic H1N1 influenza virus.
    Srivastava V; Yang Z; Hung IF; Xu J; Zheng B; Zhang MY
    J Virol; 2013 May; 87(10):5831-40. PubMed ID: 23487456
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Safety and immunogenicity of a vero cell culture-derived whole-virus H5N1 influenza vaccine in chronically ill and immunocompromised patients.
    van der Velden MV; Geisberger A; Dvorak T; Portsmouth D; Fritz R; Crowe BA; Herr W; Distler E; Wagner EM; Zeitlinger M; Sauermann R; Stephan C; Ehrlich HJ; Barrett PN; Aichinger G
    Clin Vaccine Immunol; 2014 Jun; 21(6):867-76. PubMed ID: 24739978
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Broadly Reactive H2 Hemagglutinin Vaccines Elicit Cross-Reactive Antibodies in Ferrets Preimmune to Seasonal Influenza A Viruses.
    Reneer ZB; Skarlupka AL; Jamieson PJ; Ross TM
    mSphere; 2021 Mar; 6(2):. PubMed ID: 33692193
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A broadly neutralizing human monoclonal antibody against the hemagglutinin of avian influenza virus H7N9.
    Li J; Zhang L; Bao L; Wang Y; Qiu L; Hu J; Tang R; Yu H; Shan J; Li Y; Qin C; Zhu F
    Chin Med J (Engl); 2022 Apr; 135(7):799-805. PubMed ID: 35671181
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.